What is the ticker symbol for ProQR Therapeutics N.V.?

ProQR Therapeutics N.V. trades under the ticker PRQR on NASDAQ.

What sector does ProQR Therapeutics N.V. operate in?

ProQR Therapeutics N.V. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PRQR in a portfolio?

PortView shows PRQR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

ProQR Therapeutics N.V. (PRQR) Stock Analysis

NASDAQHealthcareBiotechnology

$2.16+1.65%

1-year price historyRange $1.37 – $3.05

52-week range$2.16

$1.33$3.10

What ProQR Therapeutics N.V. does

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

Key metrics

Market cap

$226.94M

P/E (TTM)

-4.68

EPS (TTM)

$-0.46

Beta

0.03

Dividend yield

0.00%

Revenue / share

$0.17

50-day avg

$1.89

200-day avg

$1.79

52-week high

$3.10

52-week low

$1.33

CEO

Daniel Anton de Boer

ETFs linked to PRQR

Broad-market and Healthcare sector ETFs an investor holding ProQR Therapeutics N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how PRQR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze PRQR in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for ProQR Therapeutics N.V.?: ProQR Therapeutics N.V. trades under the ticker PRQR on NASDAQ.
Which exchange is PRQR listed on?: PRQR is listed on NASDAQ.
What sector does ProQR Therapeutics N.V. operate in?: ProQR Therapeutics N.V. is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze PRQR in a portfolio?: PortView shows PRQR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.